0001562180-22-002136.txt : 20220302
0001562180-22-002136.hdr.sgml : 20220302
20220302182141
ACCESSION NUMBER: 0001562180-22-002136
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220228
FILED AS OF DATE: 20220302
DATE AS OF CHANGE: 20220302
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Paggiarino Dario A.
CENTRAL INDEX KEY: 0001574261
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-51122
FILM NUMBER: 22705636
MAIL ADDRESS:
STREET 1: 4025 SORRENTO VALLEY BLVD.
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: EyePoint Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001314102
STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826]
IRS NUMBER: 262774444
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 480 PLEASANT STREET
STREET 2: SUITE B300
CITY: WATERTOWN
STATE: MA
ZIP: 02472
BUSINESS PHONE: 617-926-5000
MAIL ADDRESS:
STREET 1: 480 PLEASANT STREET
STREET 2: SUITE B300
CITY: WATERTOWN
STATE: MA
ZIP: 02472
FORMER COMPANY:
FORMER CONFORMED NAME: pSivida Corp.
DATE OF NAME CHANGE: 20080619
FORMER COMPANY:
FORMER CONFORMED NAME: pSivida LTD
DATE OF NAME CHANGE: 20050111
4
1
primarydocument.xml
PRIMARY DOCUMENT
X0306
4
2022-02-28
false
0001314102
EyePoint Pharmaceuticals, Inc.
EYPT
0001574261
Paggiarino Dario A.
C/O EYEPOINT PHARMACEUTICALS, INC.
480 PLEASANT STREET
WATERTOWN
MA
02472
false
true
false
false
Chief Medical Officer
Common Stock
2022-02-28
4
M
false
4105.00
0.00
A
19945.00
D
Common Stock
2022-02-28
4
F
false
1294.00
9.95
D
18651.00
D
Restricted Stock Units
0.00
2022-02-28
4
M
false
4105.00
0.00
D
Common Stock
4105.00
0.00
D
No shares were sold - these shares were withheld by the issuer to satisfy tax withholding requirements in connection with the Reporting Person's exercise of his withholding right following the vesting of the restricted stock units
The restricted stock units vested in three equal installments on the following dates: 6.30.2020, 2.28.2021 and 2.28.2022.
/s/ Ron Honig, Attorney-in-Fact
2022-03-02